Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.

doi:10.18632/oncotarget.6056

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.

Oncotarget - 29 Dec 2015

Kim Hyo Song, Kim Sung-Moo, Kim Hyunki, Pyo Kyoung-Ho, Sun Jong-Mu, Ahn Myung-Ju, Park Keunchil, Keam Bhumsuk, Kwon Nak-Jung, Yun Hwan Jung, Kim Hoon-Gu, Chung Ik-Joo, Lee Jong Seok, Lee Kyung Hee, Kim Dae Joon, Lee Chang-Geol, Hur Jin, Chung Hyunsoo, Park Jun Chul, Shin Sung Kwan, Lee Sang Kil, Kim Hye Ryun, Moon Yong Wha, Lee Yong Chan, Kim Joo Hang, Paik Soonmyung, Cho Byoung Chul

Abstract excerpt

The purpose of this study was to investigate the clinical activity, safety and predictive biomarkers of dacomitinib, an irreversible pan-HER inhibitor, in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M-ESCC). Patients, whose diseases were not amenable to curative treatment and had progressed on platinum-based chemotherapy, were treated with dacomitinib 45 mg/day. The primary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Esophageal Neoplasms

Share to Esophageal Squamous Cell Carcinoma

Share to Neoplasm Recurrence, Local

Share to Patient Selection

Share to Precision Medicine

Share to Quinazolinones

Share to Republic of Korea

Source

Open in PubMed Open full text

Identifiers

PMID: 26462025
DOI: 10.18632/oncotarget.6056
PMCID: PMC4792605

Genes

EGFR
FLT3
MLH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.PMID 26462025Read ↗

Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.Semantic proximity Read ↗

Tumor profiling of gastric and esophageal carcinoma reveal different treatment options.Semantic proximity Read ↗

A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.Semantic proximity Read ↗

Actionable Alterations for Molecular Targeted Therapy in Esophageal Cancer: An AACR Project GENIE ReviewSemantic proximity Read ↗

Antitumor Activity of Larotrectinib in Esophageal Carcinoma withNTRKGene AmplificationSemantic proximity Read ↗

Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus.Semantic proximity Read ↗

New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune CheckpointsSemantic proximity Read ↗

Clinical impact of tumour biology in the management of gastroesophageal cancer.Semantic proximity Read ↗

Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinomaSemantic proximity Read ↗

Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.Semantic proximity Read ↗

Anlotinib inhibits the development of esophageal squamous cell carcinoma by regulating the PI3K/AKT signaling pathwaySemantic proximity Read ↗

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.